New oral anticoagulants are intended to replace warfarin, being at least as safe and effective, and lacking some of the disadvantages of VKAs. Clinical data for dabigatran, rivaroxaban, apixaban and edoxaban, and other new drugs, are discussed in this article with special focus on their use in...
New oral anticoagulants are intended to replace warfarin, being at least as safe and effective, and lacking some of the disadvantages of VKAs. Clinical data for dabigatran, rivaroxaban, apixaban and edoxaban, and other new drugs, are discussed in this article with special focus on their use in...
73 Amiodarone, diltiazem, and verapamil increase the serum concentration of dabigatran, edoxaban, and apixaban via P glycoprotein competition.59 In addition, diltiazem and verapamil are cytochrome P450 3A4 (CYP3A4) inhibitors, resulting in a further increase in NOAC levels.59 For adults with ...
Among patients with non-valvular AF, 93,691 used NOAC and 27,496 used warfarin (Fig. 1). The NOAC users were categorized according to medications: dabigatran (n = 11,238; 12.0%), rivaroxaban (n = 28,732; 30.1%), apixaban (n = 20,019; 21.4%), edoxaban (n = ...
Recent European consensus guide- lines from 2015 recommend oral FXa inhibitors (rivaroxaban, apixaban, or edoxaban) over VKAs in the elderly if CrCl >1 5 ML/min, and in Denmark, we follow the European guidelines, but with the modification that VKA is also recommended if time in ...
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104. CAS PubMed Google Scholar Guyatt G. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines....
At present vitamin K antagonists (VKAs; i.e., warfarin) and four diverse non-vitamin K oral anticoagulants (DOACs)—apixaban, dabigatran, rivaroxaban and edoxaban—are available on the market, and can be used for stroke prevention in non-valvular AF (NVAF). While treatment with VKAs represente...
Owing to their unfavorable pharmacokinetics, VKA have a small therapeutic window, require frequent monitoring, and are susceptible to drug and nutritional interactions. A major disadvantage is that because of their indirect mechanism of action there is a lag phase of 2–3 days before a therapeutic ...